New developments suggest that the graft itself and molecules expressed within the graft microenvironment dictate the phenotype and evolution of chronic rejection.
INTRODUCTION
Current state-of-the-art immunosuppressive strategies have been most successful at inhibiting acute allograft rejection and have significantly improved short-term graft survival rates [1] . However, these same strategies have failed to interrupt the development of chronic allograft rejection, the leading cause of graft failure following solid organ transplantation [2] . It has therefore become most apparent that long-term success following transplantation will only become a reality if we develop a better understanding of factors and molecules leading to the development of chronic rejection, and we consequently design therapeutic strategies to prevent or interrupt this process. By definition, chronic rejection is an insidious process involving delayed-type hypersensitivity mechanisms, characterized by mononuclear cell infiltrates, an obliterative vasculopathy and progressive fibrosis [3, 4] . Although this process is well established to be mediated by the recipient's immunological response to donor antigen that is initiated and coordinated by CD4 þ T cells, it also involves other complex issues including adaptive and immunoregulatory responses within the graft [5] [6] [7] . New insights into roles for the innate and the adaptive immune response and T-cell and B-cell activation pertinent to rejection are reviewed in detail in other sections of this issue. Here, we focus our discussion on how the graft itself and events within the graft are critical determinants of the initiation and evolution of chronic rejection.
We recently described a paradigm in which changes in the integrity of microvascular endothelial cells (EC) within a graft creates a microenvironment leading to the local expression of cytokines and growth factors, including vascular endothelial growth factor (VEGF), that are mechanistic to promote and/or sustain chronic allograft rejection [6, 8] . In this model, we propose that direct injury to the graft EC resulting from ischemia-reperfusion injury, cellular and humoral alloimmune targeting elicits a cascade of events initiated by local tissue hypoxia and the local overexpression of VEGF. Direct targeting of the EC, for instance by cytotoxic T cells or alloantibodies results in local hypoxia and tissue injury [9 && ,10,11]. Nevertheless, it is somewhat underappreciated that mononuclear cell infiltrates stimulate EC proliferation and a leukocyteinduced angiogenesis reaction [12, 13] that promotes local tissue hypoxia [6, [14] [15] [16] . Also, the binding of alloantibody to EC and the local effects of cytokines and growth factors can stimulate proliferative signaling within activated EC [10, [17] [18] [19] [20] . Furthermore, the number of pericytes that colocalize with EC is decreased in association with chronic inflammation, thereby compromising the structural integrity of the microvascular bed [6, 21, 22] . We [6, 8] and others [22, 23] suggest that disruption of EC homeostasis creates abnormal microvascular blood flow patterns within a graft that result in local hypoxia. All of these events (injury, proliferation, perciyte loss and hypoxia) have potential to precede the process of endothelial-to-mesenchymal transition [24, 25] resulting from the dedifferentiation of EC into fibroblasts that ultimately is associated with collagen production and fibrosis development. Consistent with this model, we propose that early stabilization of the microvasculature has potential to inhibit the progression of chronic rejection. This possibility will be discussed in more detail below. Nicolls' group recently characterized timedependent changes in the microvasculature that occur during chronic allograft rejection [22] . Consistent with older studies from our laboratory [14, 16, 18, 26] , they demonstrated that remodeled microvasculature is markedly disorganized within grafts and, similar to tumors [27] , is temporally and spatially associated with interstitial infiltrates and local tissue hypoxia. In chronic rejection, many CD31 þ vessels were found to lack pericytes indicating that their structural integrity may be disrupted [22] . Several proangiogenic growth factors, including VEGF, are induced by local tissue hypoxia through the transcriptional activity of hypoxia-inducible factor 1a (HIF-1a) [23, 28] . Jiang et al. [22] demonstrated that these changes are associated with tissue hypoxia following orthotopic tracheal transplantation, and examined roles for HIF-1a in the remodeling repair response. Using a conditional knockout, it was observed that deletion of HIF-1a results in accelerated graft failure [22] , whereas transient overexpression of HIF-1a within the graft (using a viral vector) limited intragraft hypoxia, preserved microvascular integrity and prolonged graft function. Thus, HIF-1a-dependent events within a graft may result in physiological protective responses that sustain microvascular integrity. Overexpression of HIF-1a within grafts was also associated with the induced expression of several proangiogenic factors including CXCL12 (stromal cell-derived factor 1), placental growth factor and VEGF. These angiogenesis growth factors also promote the recruitment of infiltrates and have potent proinflammatory properties [26, [29] [30] [31] . It is thus not surprising that hypoxic and/or HIF-1a-expressing grafts had extensive inflammatory infiltrates [15, 22] . Overall, it appears that early injury and local hypoxia can drive a cycle of events that result in ongoing inflammation through the induction of proangiogenic factors.
CENTRAL ROLE FOR VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE CHRONIC REJECTION INTRAGRAFT MICROENVIRONMENT
There are significant data to suggest that the overexpression of VEGF may be central to the pathological intragraft microenvironment. As discussed above, overexpression of VEGF within the graft may be a consequence of microvascular injury, local tissue hypoxia and HIF-1a-dependent responses. Intragraft VEGF may also result from delivery by infiltrating leukocytes within the local microenvironment. Indeed, several recent studies indicate that VEGF levels can be monitored as an index of risk for the development of rejection and/or graft failure [32 & ,33-36] . Most notably, in animal models, delivery and/or forced overexpression of VEGF within cardiac allografts mobilize bone marrow-derived monocyte/macrophages and accelerate the development of allograft vasculopathy [37] . There is a general consensus that VEGF is a dominant factor mediating vascular remodeling, and it is possible that its expression is a key physiological response to enable repair following acute and chronic injury [38] . However, its newly described effects on the chemotaxis and activation of effector T cells [39] [40] [41] and its potential effects on immunoregulatory T cells [42] [43] [44] [45] have broad biological and clinical implications for the understanding of chronic rejection.
The VEGF receptors (VEGFRs) Flt-1 (VEGF receptor 1) and KDR (VEGF receptor 2) may be expressed by T cell subsets [40] [41] [42] [43] [44] [45] , and VEGF-VEGFR interactions promote lymphocyte chemotaxis in vitro and in vivo [26, 40, 41] . Furthermore, VEGFR-expressing T cells have been found to accumulate within rejecting human allografts in vivo [41] , suggesting that locally expressed VEGF may interact with VEGFRs expressed on circulating subsets of T cells [39, 41] . VEGF-VEGFR interactions facilitate the transmigration of selected populations of previously activated and/or memory CD4 þ and CD8 þ T cells across activated EC in vitro [41] , the intragraft accumulation of T cell infiltrates [26, 39, 41] and the development of allograft vasculopathy in the humanized SCID mouse [39] . In models of acute rejection, antibodies to VEGF or to the classical VEGFRs (Flt-1 and KDR) prolong graft survival [26, 39, 41, [46] [47] [48] further suggesting that VEGF has a potent proinflammatory function in association with alloimmunity. Since the induced expression of VEGF and VEGFR-mediated signals require activation of the Akt/mammalian target of rapamycin (mTOR) signaling pathway [49, 50] , these observations also suggest that mTOR inhibitors (mTORi) may have potential to attenuate VEGF-dependent biology within the graft. As will be discussed below, it is also possible that cell intrinsic modulation of the Akt/mTOR signaling pathway may interrupt the progression of chronic rejection [51] .
SEMAPHORIN-NEUROPILIN INTERACTIONS WITHIN THE GRAFT MICROENVIRONMENT AND THE DEVELOPMENT OF CHRONIC REJECTION
The neuropilins (NRP) were originally identified as receptors for the semaphorins, but they are now well established as nonclassical VEGF receptors expressed by multiple cell types including subsets of T cells and antigen-presenting cells (APCs) [40,42,45,52 & ,53] . They are single spanning transmembrane glycoproteins that function as chemorepulsive mediators in neurons [54] . NRP-1 was found to be a receptor for the class 3 semaphorin, semaphorin 3A (Sema3A), whereas another semaphorin, Sema3F, also known to inhibit axonal guidance, was observed to be selective in its binding for NRP-2 [55, 56] . Klagsbrun's group [57, 58] coincidentally identified NRP-1 and NRP-2 as VEGFRs on endothelial cells, and they are now known to play a major role in vasculogenesis, angiogenesis and tumor growth [59, 60] . Nevertheless, little is reported on the interactions between VEGF and its accessory neuropilin receptor on T cells.
Recent studies indicate that NRP-1 may have significant biological effects in T cells to elicit regulatory signaling responses. NRP-1 is well established to be most selectively expressed by immunoregulatory CD4 þ T-cell subsets (Tregs) [40,45,61 && ]. Some reports suggest that its expression is dominant on natural thymic-derived Tregs (nTregs) [45, 62] , whereas other studies suggest that its expression is not necessarily selective to nTregs [40, 61 && ,63,64] and may be prominent on expanded pooled populations of Foxp3 þ Tregs, including in-vitro-induced iTregs. Interestingly, VEGF-NRP-1 interactions may stimulate chemoattraction and have been reported to guide NRP-1 þ Tregs into tumors [63] . Knockdown of NRP-1 on CD4 þ Foxp3 þ Tregs was found to restrict the infiltration of Tregs into tumors, which limits local immunoregulation and results in an efficient antitumor immune response. Whether this effect is entirely related to NRP-1 expression, rather than other VEGFRs on T cells [44] , is not known, but it is likely that this biology is of great relevance in the development of chronic rejection. For instance, if intragraft hypoxia stimulates the overexpression of VEGF, it is entirely possible that this response may enable the recruitment of NRP-expressing Tregs, which have potential to promote intragraft immunoregulation. In this manner, intragraft VEGF has potential to promote the local recruitment of both effectors and Tregs and thus, the relative expansion of NRP-1 þ Foxp3 þ Tregs in individual patients will determine outcome.
It is possible that local intragraft expression of semaphorins may interact with NRP receptors on T cells and elicit a regulatory response. The class 3 family of semaphorins were identified as negative mediators of axon migration and as angiogenesis inhibitors via their interactions with the NRPs [65] . They are produced by multiple cell types, including T cells [66] and epithelial cells [67, 68] and they bind to a dimeric NRP complex and recruit and activate cell surface plexins (notably plexins A1-A4). Plexins activate downstream regulatory signaling responses [69, 70] . It has also been reported that Sema3A, 3F and 3C [66, 71] reported that selective knockout of NRP-1 on T cells abrogated Treg function in vitro and in vivo. Solomon et al. [72] found that the lack of NRP-1 on T cells was associated with increased severity of disease in a model of experimental allergic encephalitis (EAE) and that Tregs deficient for NRP-1 fail to suppress T effectors in vitro and in vivo. Yuan et al. [73] demonstrated that adoptive transfer of CD4 þ CD25 -NRP-1 þ , but not NRP1 -, T cells into a fully mismatched mouse model of cardiac allotransplantation resulted in long-term graft survival. Also, the local overexpression of VEGF within a graft has potential to recruit NRP-1 þ Tregs to the local site. However, the unanswered question is whether the production of semaphorins within a graft is required for optimal intragraft immunoregulation. To date, current findings indicate that the expression of soluble semaphorin 3 family molecules (for instance by infiltrating activated effector T cells) or membrane-bound semaphorin 4 family molecules 
NEW INSIGHTS INTO mTOR SIGNALING AS A MODULATOR OF THE CHRONIC REJECTION INTRAGRAFT MICROENVIRONMENT
An implication of an endothelial-based injury/ repair model of chronic rejection is that microvascular stability must be sustained to maintain a physiological intragraft microenvironment. We thus suggest that the design of therapeutics that target EC activation and/or augment proresolution intracellular signaling pathways in EC will inhibit the development of chronic rejection. To this end, activity of the mTOR/Akt signaling pathway is critical for EC activation, survival and proliferation [6, 50, 74] ] and the production of VEGF [78], which, as discussed above, may be a central mediator of chronic rejection. Targeting mTOR has been shown to reduce VEGF expression [74] , VEGF-induced angiogenesis [50, 74] and leukocyte-induced angiogenesis in association with inflammation [8, 78] . Several observations also suggest that mTOR-dependent activation of Akt is implicated in the production of VEGF [78], in angiogenesis [50] , and in other EC The importance of alloantibody-targeting of EC in the pathogenesis of chronic rejection is well established, but recent molecular studies indicate that persistent donor specific antibody (DSA)-mediated graft injury is dominated by EC transcripts [10, 11] . Indeed, it appears that the pathogenicity of individual donor-specific alloantibodies is associated with their effect(s) on the targeting of EC and their ability to elicit an EC-dependent intracellular signaling response [11, 20] . Consistent with this observation, Reed's group has demonstrated that alloantibody-mediated activation of EC involves mTOR/Akt-dependent signaling [17, 82] , and that this response facilitates monocyte recruitment into the graft in part via EC expression of P-selectin [83 & ]. They further observed that treatment with mTORi inhibits alloantibody-induced EC activation and proliferation [84 && ]. Collectively, these observations suggest that mTORi represent EC-targeted therapeutic agents with high potential to inhibit activation and proliferation. mTORi's also attenuate the EC proinflammatory phenotype, and thus stabilize the microvascular bed and inhibit the progression of chronic rejection.
Harnessing cell intrinsic mechanisms of EC stability may also have potential to limit activation responses associated with inflammation. We recently speculated that signaling pathways that elicit the process of inflammation resolution following activation may lead to targeted anti-inflammatory therapeutics. Our initial approach involved the identification of endogenous inhibitors of the mTOR signaling pathway in EC. We recently reported that an adaptor called DEP domain-containing mTOR-interacting protein (DEPTOR) that is known to modulate mTOR signaling [85] has marked effects on EC activation responses [77 & ]. DEPTOR is expressed at high levels in different microvascular EC beds in vitro and in vivo, and its expression is markedly reduced in EC following activation [77 & ]. Knockdown of DEPTOR in EC using siRNA resulted in a dramatic activation response that included the overexpression of chemoattractant chemokines and adhesion molecules and a phenotype that supported the adhesion of leukocytes in vitro. In addition, we found that DEPTOR was functional to regulate an angiogenesis response, which is consistent with its effects to modulate mTORC1 activity. In pilot experiments, we also find that forced overexpression of DEPTOR in EC inhibits the expression of TNF-a-induced adhesion molecules, which translates into a prolonged survival of cardiac allografts [unpublished data]. These findings exemplify the importance of endogenous inhibitors of the mTOR pathway and the potential that they can be harnessed to stabilize the intragraft microvascular bed and thus improve graft survival. We have focused our opinion on mTOR signaling in EC, and the potential that mTORi therapeutics stabilize the intragraft microenvironment. However, we wish to emphasize that other relevant pathways such as the cytokine-induced nuclear factor-kB activation response may also be be targeted by novel compounds such as N-octanoyl dopamine [86, 87] . Thus, several new therapeutics are on the horizon that may suppress activational events that sustain the progression of chronic rejection.
OTHER NEW INSIGHTS
We acknowledge that the critical balance between host alloimmunity versus tolerance has a critical impact on the evolution of chronic rejection, and we strongly suggest that host immunocompetence may define events within the intragraft microenvironment. Host alloimmunity is discussed in other sections of this issue. mTOR signaling, while key to microvascular stability, is also well established to function in T effector, and not in T regulatory cell activation [88] ; thus, mTORi's may regulate both the graft EC as well as host immunity. Powells' group has published extensively on this biology using knockout [89] and knockdown [90] approaches, and more recently demonstrated a key function for mTOR in Th1 and Th17 differentiation, but not in Tregs expansion and activity [90] . In contrast, Chi's group demonstrated that total deletion of mTORC1 in Treg, using a Foxp3 cre Raptor fl/fl mouse model, resulted in a striking deficiency in Treg function, indicating that mTORC1 may also function in Tregs [91 && ]. However, pharmacological mTORi's including rapamycin only partially inhibit mTORC1. This suggest that low mTORC1 activity [64, 92] or oscillatory activity [93] is required to promote Treg expansion, stability and function. Low mTORC1 activity may also be required to maintain EC survival, and a quiescent phenotype within the graft [76 && ]. This possibility also suggests that mTORi's allow for immunoregulation as a consequence of interactions between the graft microenvironment and the host.
Another area of great importance involves the function of neuropilin family molecules on T cells, notably NRP-1 þ Foxp3 þ Tregs. A significant body of data suggests that ligation of NRP-1 by semaphorin family molecules results in the inhibition of intracellular Akt/mTOR signaling [61 && ,94] . Although it is likely that semaphorins are expressed by multiple cells within allografts, it is theoretically possible that expression levels vary in different organs and/or that their function within the graft microenvironment will augment Treg stability and function. Understanding how the expression of semaphorins within a graft may interact with Tregs has significant therapeutic implications for the future.
Finally, as discussed above, the intragraft expression of cytokines and chemokines is well established to mediate chemoattraction of different subsets of T cells, including T effector and Treg cells into the graft. Contrary to expectations, using a singlecell visualization microfluidic model, we recently observed a process whereby the same chemokines may elicit a process of chemoinhibition [95 & ], and that selected receptor-mediated signals and/or molecules dictate directionality of the leukocyte migration response [95 & ]. It is entirely possible that there are population-based leukocyte responses, but this study indicates that individual leukocytes may migrate in opposite directions in response to an identical chemokinetic gradient. These observations further suggest that receptor-mediated signals within subsets of leukocytes dictate the directionality of migration, and that monitoring intragraft factors that elicit a chemoinhibitory response will have great impact for the development of future therapeutics.
CONCLUSION
In conclusion, the failure of potent immunosuppressive agents to impact the initiation or the progression of chronic rejection has promoted a 'fresh look' into this disease process. In the absence of true tolerance, we suggest that changes in the intragraft microenvironment can dictate the phenotype of rejection and the chronic rejection process. Our focus on events within the graft indicates that new molecules, regulated by HIF-1a-dependent events, and semaphorins and neuropilins have high potential to impact this process. We also strongly believe that mTOR/Akt signaling can dictate the proinflammatory versus the tolerogenic phenotype of the graft EC as critical determinants of the initiation and evolution of chronic rejection. In this study, the authors pretreated EC with an mTORi, and find that subsequent TNF-a-activation fails to result in VCAM-1 expression and an associated adhesion and capture of T cells in vitro under flow conditions. They subsequently demonstrated that this effect could be reproduced using a rictor knockdown approach (but not raptor knockdown) implicating mTORC2-dependent and Akt-dependent activation as critical signals in the proinflammatory function of EC. 76. In this study, the authors pretreated EC with an mTORi and find that following subsequent IFNg-treatment, they fail to reactivate memory CD4 þ T cells and expanded a CD4 þ CD25 hi FoxP3 þ population of Treg. They subsequently linked this effect to the overexpression of PD-L1 and PD-L2 on mTORi-treated EC. This study suggests that mTORi alter the immunogenicity of EC toward a phenotype that prevents proinflammation, and further suggests that the phenotype may support immunoregulation. In this study, we observed that EC express high levels of DEPTOR, and that it serves as an endogenous inhibitor of mTORC1, MAPK and STAT1 activation. Furthermore, we found that knockdown of DEPTOR in EC resulted in a striking activation response with more than 300-fold induction in chemokine expression and a marked increase in the expression of adhesion molecules. This effect translated into augmented leukocyte-and CD3 þ T cell-endothelial adhesion in DEPTOR knockdown cells. These findings define DEPTOR as an important endogenous inhibitor of EC activation. In this study, the authors demonstrate that anti-HLA class 1 antibodies activate intragraft EC, and promote monocyte-binding and monocyte/macrophage accumulation. Furthermore, they demonstrate that this effect is in part mediated by EC expression of P-selectin and can be inhibited by rPSGL-1-Ig.
